2027 ICD-10-CM Diagnosis Code C74.02Malignant neoplasm of cortex of left adrenal gland
ICD-10-CM Codes›C00–D49›C73-C75›C74
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 22
- Chronic Condition
C74.02 is a billable ICD-10-CM diagnosis code for malignant neoplasm of cortex of left adrenal gland. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 643 through 645. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 25 closely related codes. Coders also document this condition as malignant neoplasm of adrenal cortex. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Endocrine system cancers - adrenocortical.
For Medicare Advantage risk adjustment, C74.02 maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers) under the V28 model, adding a risk factor of about 0.363 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C74.02 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Malignant neoplasm of adrenal cortex
- Primary malignant neoplasm of adrenal cortex
- Primary malignant neoplasm of left adrenal cortex
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to C74.02: its own notes plus those printed at Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name C74.02, its category, or a range that includes it.
Applicable To 2
These notes mention C74.02.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Malignant Adrenal Gland Neoplasm
a primary or metastatic malignant neoplasm that affects the adrenal gland.
Table of NeoplasmsClinical
Patient EducationClinical
Adrenal Gland Cancer
Your adrenal, or suprarenal, glands are located on the top of each kidney. These glands produce hormones that you can't live without, including sex hormones and cortisol, which helps you respond to stress and has many other functions.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C74.02 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C74.02Overview
What is the ICD-10 code for malignant neoplasm of cortex of left adrenal gland?
The ICD-10-CM code for malignant neoplasm of cortex of left adrenal gland is C74.02 (sometimes written as C7402). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is C74.02 (Malignant neoplasm of cortex of adrenal gland) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of cortex of left adrenal gland on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does C74.02 group to?
When malignant neoplasm of cortex of left adrenal gland is the principal diagnosis on an inpatient stay, it groups to MS-DRG 644, 645, 643, with relative weights from 0.7461 to 1.6138 depending on complications. Higher weights mean higher Medicare reimbursement.
Is C74.02 a CC or MCC?
CMS lists C74.02 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 25 closely related codes in its exclusion list.
What is the ICD-9 equivalent of C74.02?
Under the General Equivalence Mappings, malignant neoplasm of cortex of left adrenal gland converts to ICD-9-CM 194.0 (malign neopl adrenal). The mapping is approximate, so confirm the match fits the documentation.
What HCC is C74.02?
C74.02 (malignant neoplasm of cortex of left adrenal gland) maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers), commonly written as HCC 22, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 10 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does C74.02 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C74.02 adds a risk adjustment factor of about 0.363 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.314 to 0.410 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, and HCC 21) supersedes it when both are reported. See the full factor table on the HCC 22 category page.
